• 1
    Medsger TA Jr, Steen V. Classification prognosis. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 5164.
  • 2
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 244554.
  • 3
    Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 1517.
  • 4
    Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 282835.
  • 5
    White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. Arthritis Rheum 1995; 38: 35160.
  • 6
    Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 7
    Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008; 34: 16179.
  • 8
    Clements P, Medsger TA Jr, Feghali C. Cutaneous involvement in systemic sclerosis. In: ClementsP, FurstDE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 12950.
  • 9
    Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 25573, vi.
  • 10
    Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 243744.
  • 11
    Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 242231.
  • 12
    Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum 1993; 36: 15759.
  • 13
    Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al, on behalf of the CAT-192 Study Group and the Scleroderma Clinical Trials Consortium. Recombinant human anti– transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 32333.
  • 14
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194203.
  • 15
    Khanna D, Clements PJ, Furst DE, Korn JH, Ellman MM, Rothfield N, et al, for the Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60: 110211.
  • 16
    Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58: 181022.
  • 17
    Steen VD, Medsger TA Jr, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97: 6529.
  • 18
    Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991; 18: 1496503.
  • 19
    Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 18926.
  • 20
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-Penicillamine Study. Ann Rheum Dis 2006; 65: 13259.
  • 21
    Seibold JR, Clements PJ, Korn JH, Ellman M, Rothfield NF, Wigley FM, et al. U.S. phase III trial of relaxin in diffuse scleroderma [abstract]. J Rheumatol 2001; 28 Suppl 63: 55.
  • 22
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al, for the Relaxin Study Group and the Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 23
    Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007; 16: 108392.
  • 24
    Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a difference in the score of the Health Assessment Questionnaire-Disability Index? Analysis from a scleroderma clinical trial. J Rheumatol 2008; 35: 4668.
  • 25
    Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, et al. Effects of the American College of Rheumatology Systemic Sclerosis Trial Guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology (Oxford) 2001; 40: 61522.